Cargando…

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection

OBJECTIVES: The aim of this study was to evaluate the susceptibilities of Clostridium difficile isolates to cadazolid, a novel antibiotic for the treatment of C. difficile infection. METHODS: Ribotyping and susceptibilities were determined for C. difficile isolates from a multicentre, double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerding, D. N., Hecht, D. W., Louie, T., Nord, C. E., Talbot, G. H., Cornely, O. A., Buitrago, M., Best, E., Sambol, S., Osmolski, J. R., Kracker, H., Locher, H. H., Charef, P., Wilcox, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681371/ https://www.ncbi.nlm.nih.gov/pubmed/26433782 http://dx.doi.org/10.1093/jac/dkv300

Ejemplares similares

Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis
por: Muhammad, Aziz, et al.
Publicado: (2020)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Role of cephalosporins in the era of Clostridium difficile infection
por: Wilcox, Mark H., et al.
Publicado: (2017)

Non-toxigenic Clostridioides (Formerly Clostridium) difficile for Prevention of C. difficile Infection: From Bench to Bedside Back to Bench and Back to Bedside
por: Gerding, Dale N., et al.
Publicado: (2018)

Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2016)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

Toxin B is essential for virulence of Clostridium difficile
por: Lyras, Dena, et al.
Publicado: (2009)

Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
por: Bunnell, Kristen L., et al.
Publicado: (2017)

Concomitant Vancomycin-Resistant Enterococcus faecium and Clostridium difficile Colitis
por: Mehershahi, Shehriyar, et al.
Publicado: (2021)

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
por: Crook, Derrick W., et al.
Publicado: (2012)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
por: Lee, Christine, et al.
Publicado: (2016)

Structural basis of translation inhibition by cadazolid, a novel quinoxolidinone antibiotic
por: Scaiola, Alain, et al.
Publicado: (2019)

Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection
por: Baines, Simon D., et al.
Publicado: (2015)

Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection
por: Malamood, Mark, et al.
Publicado: (2015)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses
por: Cornely, Oliver A., et al.
Publicado: (2019)

The Challenging Conundrum of Diagnosing and Managing Clostridium difficile Infection
por: Gerding, Dale N., et al.
Publicado: (2017)

Clostridium: Transmission difficile?
por: Harbarth, Stephan, et al.
Publicado: (2012)

Etiology of Infectious Diarrhea in Patients Tested for Clostridium difficile: If It Isn’t Clostridium difficile, What Is It?
por: Kwon, Jennie H, et al.
Publicado: (2017)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Piperacillin/tazobactam/vancomycin: Clostridium difficile colitis: case report
Publicado: (2021)

Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection
por: Gonzales, Milagros, et al.
Publicado: (2010)

A Review of Mixed Strain Clostridium difficile Colonization and Infection
por: Dayananda, Pete, et al.
Publicado: (2019)

An Analysis of Clostridium difficile Environmental Contamination During and After Treatment for C difficile Infection
por: Davies, Kerrie, et al.
Publicado: (2020)

Absence of toxin gene transfer from Clostridioides difficile strain 630Δerm to nontoxigenic C. difficile strain NTCD-M3r in filter mating experiments
por: Sambol, Susan P., et al.
Publicado: (2022)

Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient
por: Mahabir, Shanti, et al.
Publicado: (2013)

Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin
por: Sambol, Susan P., et al.
Publicado: (2023)

Toxinotype V Clostridium difficile in Humans and Food Animals
por: Jhung, Michael A., et al.
Publicado: (2008)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness
por: Cornely, Oliver A, et al.
Publicado: (2018)

Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin
por: Lao, Dominador, et al.
Publicado: (2012)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
por: Tannous, George, et al.
Publicado: (2010)

Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
por: Zhang, Kevin, et al.
Publicado: (2019)

Evolutionary History of the Clostridium difficile Pathogenicity Locus
por: Dingle, Kate E., et al.
Publicado: (2013)

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study
por: Vickers, Richard J, et al.
Publicado: (2017)

Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection
por: Chilton, C. H., et al.
Publicado: (2016)

Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination
por: Erikstrup, Lise Tornvig, et al.
Publicado: (2015)

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_unp2giims93m2di3pjsrmna8q6